Executing a successful remediation program: part 2 of 3

Published: 17-Mar-2025 Featured companies: NSF

Learn how NSF's Pharma Biotech experts help clients with remediation strategy, including FDA Warning Letters.

Executing a successful remediation program: part 2 of 3

The second part of this three-part series on executing an effective remediation program starts by looking at primary versus secondary root causes. A robust quality system provides an assurance of high-quality production efforts and products. NSF recommends that a systems-based approach to remediation and corrective action is the most successful approach. Also, a system- based approach is recognised globally with, regulators such as the MHRA and FDA.

Read part one of the series here

Read part three of the series here

Click here to read more about executing a successful remediation program

Featured companies

Founded in 1944, NSF’s mission is to protect and improve global human health. NSF, Pharmaceutical Services provides a comprehensive range of independent, third-party...
See more

You may also like

Manufacturing
New legal duties for QPs in decentralised manufacturing

New legal duties for QPs in decentralised manufacturing

Read more
In this clip, Dr. Peter Gough explains that QPs will be responsible for supervising decentralised activities, conducting regular audits, carrying out periodic on-site visits, confirming GMP compliance to regulatory authorities and notifying changes that may affect quality or safety

Trending Articles

  1. FDA escalates action against Dabur India over systemic data-integrity and cGMP failures The US FDA has issued a warning letter to Dabur India following an inspection that identified falsified records, missing laboratory data, inadequate cleaning and process validation and weaknesses in quality-unit oversight, saying the company's response failed to address the systemic nature of the deficiencies
  2. AstraZeneca-BMS $400bn merger could reshape US pharma manufacturing A potential AstraZeneca acquisition of Bristol Myers Squibb would create a near-$400bn pharma giant, combining major oncology portfolios and extensive US manufacturing operations
  3. Ratio Therapeutics raises $70m to expand radiopharmaceutical manufacturing The Series C financing will support clinical development of Ratio’s Ac-225 radiotherapeutic pipeline and expansion of its radiopharmaceutical manufacturing infrastructure
  4. Eli Lilly’s retatrutide hits Phase III goals with FDA filing planned for 2027 Lilly’s triple GIP/GLP-1/glucagon agonist delivered up to 22.6% weight loss in two Phase III trials, with the company now completing its CMC package ahead of a planned US regulatory submission
  5. Thermo Fisher Scientific launches new general purpose centrifuges with natural refrigerant cooling New X2 and S2 Series centrifuges combine precise performance with improved sustainability for research, biopharma and clinical laboratories

Relevant companies

See more

Upcoming event

CPhI Milan

6–8 October 2026 | Exhibition | Fiera Milano, Italy See all

You may also like

Manufacturing
New legal duties for QPs in decentralised manufacturing

New legal duties for QPs in decentralised manufacturing

In this clip, Dr. Peter Gough explains that QPs will be responsible for supervising decentralised activities, conducting regular audits, carrying out periodic on-site visits, confirming GMP compliance to regulatory authorities and notifying changes that may affect quality or safety
Regulatory
Why FDA inspectors focus on senior management oversight and quality culture

Why FDA inspectors focus on senior management oversight and quality culture

Learn why executive oversight matters, how inspectors evaluate quality culture, and what organisations should do before an inspector arrives on site
Regulatory
FDA inspection readiness: How to prepare for surveillance and pre-approval inspections

FDA inspection readiness: How to prepare for surveillance and pre-approval inspections

Learn how to prepare for surveillance and pre-approval inspections, build a culture of continuous compliance and reduce regulatory risk
Regulatory
FDA inspection outcomes explained: Form 483, VAI, OAI, and effective regulatory responses

FDA inspection outcomes explained: Form 483, VAI, OAI, and effective regulatory responses

Learn what a Form FDA 483 means, how to develop an effective response within 15 business days, and how FDA evaluates inspection outcomes and regulatory risk
Regulatory
What’s changing at the FDA? Dr. Julia Marré explains the new U.S. regulatory landscape

What’s changing at the FDA? Dr. Julia Marré explains the new U.S. regulatory landscape

From shifting expectations around submissions to evolving agency–industry interactions, Dr. Marré breaks down what companies need to know to stay compliant, competitive, and prepared
Regulatory
AI in pharma: Practical use cases transforming research, regulatory and medical affairs

AI in pharma: Practical use cases transforming research, regulatory and medical affairs

AI and digital transformation expert Sarah Chan explores the rapidly expanding role of artificial intelligence across the pharmaceutical value chain
Pharma 5.0
AI, drug shortages & global regulation

AI, drug shortages & global regulation

Dr. Peter Gough delivers a comprehensive regulatory update focused on two global priorities shaping today’s pharmaceutical landscape: artificial intelligence (AI) and drug shortages
Subscribe now